Feels like we have been waiting for quite a while for the Dexcom G7 to be released. With the release date earmarked for end of 2021, that deadline is looming and now it’s looking more likely to be 1st quarter 2022.
The new Dexcom device will be 60% smaller than the G6 and about the same size as the Libre 2. Libre 3 looks like will be smaller yet again.
Talking about Dexcom G7 Clinical Trials, there are several trials underway, but there’s no available public data as yet. There are studies ongoing in 13 states in the USA.
It is a complete overhaul for Dexcom with the G7. Moving in the direction of major competitor Abbott’s FreeStyle Libre with a disposable system that is an all in one transmitter and sensor. Once done, just peel it off and dispose of it. Also now looking to compete with the Libre for size. Previously Libre had the measure of Dexcom with a more subtle and sleek design. The G7 is supposedly 60% smaller than the G6.
Talking with the Dexcom engineers (we have some inside contacts) the G7 will still need support from a Dexcom overlay patch as there will still be plenty of catching on doors and coming loose while sweating and swimming. The 30 minute warm-up time will also please many Dexcom fans.
The MOBILE Study published in the Journal of the American Medical Association demonstrated better glycemic control with the G7 in adults with Type 2 diabetes. It is interesting to see Type 2’s now being studied for CGM’s. This indicates a large market expansion to help improve glycemic control for people with Type 2.
The G7 will integrate with all your smart devices and will even be able to be picked up by an Apple watch. The alerts and customizable alerts are still to be released but we can only image improvements in this realm.
Dexcom has also presented data demonstrating improved accuracy for their new device, showing improved accuracy vs the G6 and vs the Libre.
Calibration is a thing of the past, thankfully.
The G7 will still be a 10-day sensor and we can expect that Dexcom are working on how to extend the length to 14 days to compete with the Libre
A view of the G7 vs the G6
The G6 is priced at around $3,800 USD / year. Dexcom have been tight lipped about the pricing for the G7, with some leaked reports suggesting similar pricing to the G6. With the Libre priced lower than the G6, Dexcom will need to stay competitive as the Libre 3 with its alarms and alerts and improved accuracy will have the measure of Dexcom on most fronts, giving Dexcom no room to suggest a premium price for a device that doesn’t deliver on other fronts.
Dexcom will be applying to all the usual ‘payers’, insurance companies and government reimbursement bodies such as the TGA as this will be the fastest way to profit. As is usual, there will be a gradual global release as the various authorities assess the data and determine the value of the G7 to the community.
Authors Opinion: The Dexcom G7 catches up with the Abbott Freestyle Libre offering. This competition is good for us all as it means better tech at better prices. This market will continue to be competitive with a dozen companies all working on bringing new Continuous Glucose Monitor tech to market. It’s a good time to be a person with diabetes, if that’s any consolation.